Financial reports
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
21 Mar 24
8-K
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
14 Mar 24
8-K
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
9 Nov 23
8-K
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
8 Aug 23
8-K
Departure of Directors or Certain Officers
23 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Departure of Directors or Certain Officers
12 Jun 23
8-K
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
11 May 23
8-K
Securities Purchase Agreement
13 Apr 23
8-K
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
23 Mar 23
Registration and prospectus
S-3
Shelf registration
9 Apr 24
S-8
Registration of securities for employees
12 Jan 24
S-3
Shelf registration
27 Dec 23
S-8
Registration of securities for employees
29 Jun 23
S-3
Shelf registration
11 May 23
S-8
Registration of securities for employees
11 Jan 23
424B5
Prospectus supplement for primary offering
11 Aug 22
S-8
Registration of securities for employees
11 Aug 22
S-8
Registration of securities for employees
12 Jan 22
424B3
Prospectus supplement
13 Dec 21
Proxies
DEF 14A
Definitive proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Jun 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
DEFA14A
Additional proxy soliciting materials
27 May 21
DEF 14A
Definitive proxy
30 Apr 21
PRE 14A
Preliminary proxy
20 Apr 21
Other
EFFECT
Notice of effectiveness
22 Apr 24
EFFECT
Notice of effectiveness
10 Jan 24
CORRESP
Correspondence with SEC
5 Jan 24
UPLOAD
Letter from SEC
2 Jan 24
CT ORDER
Confidential treatment order
22 May 23
EFFECT
Notice of effectiveness
22 May 23
CORRESP
Correspondence with SEC
17 May 23
UPLOAD
Letter from SEC
17 May 23
CT ORDER
Confidential treatment order
16 Mar 22
EFFECT
Notice of effectiveness
13 Dec 21
Ownership
SC 13G/A
FMR LLC
10 Apr 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
25 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
SC 13G
Vivo Opportunity Fund Holdings, L.P.
20 Mar 24
SC 13D/A
Growth Equity Opportunities V, LLC
18 Mar 24
4
STELIOS PAPADOPOULOS
15 Mar 24
SC 13G
DAFNA Capital Management LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
6 Feb 24
4
CRISPINA CALSADA
18 Jan 24